Healthcare provider profile · identity verified

Fausto Lanao, MD

Internal Medicine · WATERBURY, CT · NPI 1801844675

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	545	146
Amlodipine Besylate	Amlodipine Besylate	495	138
Rosuvastatin Calcium	Rosuvastatin Calcium	406	115
Fluticasone Propionate	Fluticasone Propionate	250	90
Pantoprazole Sodium	Pantoprazole Sodium	247	84
Lisinopril	Lisinopril	246	66
Losartan Potassium	Losartan Potassium	246	66
Metformin Hcl	Metformin Hcl	224	63
Metoprolol Succinate	Metoprolol Succinate	204	58
Levothyroxine Sodium	Levothyroxine Sodium	193	50
Pravastatin Sodium	Pravastatin Sodium	187	50
Furosemide	Furosemide	144	43
Gabapentin	Gabapentin	117	30
Potassium Chloride	Potassium Chloride	115	29
Albuterol Sulfate Hfa	Albuterol Sulfate	104	39
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	104	25
Omeprazole	Omeprazole	101	29
Ozempic	Semaglutide	101	26
Memantine Hcl	Memantine Hcl	89	17
Metoprolol Tartrate	Metoprolol Tartrate	89	24
Tamsulosin Hcl	Tamsulosin Hcl	89	29
Escitalopram Oxalate	Escitalopram Oxalate	78	20
Glimepiride	Glimepiride	78	23
Hydrochlorothiazide	Hydrochlorothiazide	72	24
Alendronate Sodium	Alendronate Sodium	68	19
Diclofenac Sodium	Diclofenac Sodium	64	26
Tradjenta	Linagliptin	60	17
Prednisone	Prednisone	59	48
Sertraline Hcl	Sertraline Hcl	58	17
Labetalol Hcl	Labetalol Hcl	57	13
Montelukast Sodium	Montelukast Sodium	54	16
Clopidogrel	Clopidogrel Bisulfate	50	16
Eliquis	Apixaban	50	suppressed
Simvastatin	Simvastatin	50	13
Trazodone Hcl	Trazodone Hcl	48	19
Triamcinolone Acetonide	Triamcinolone Acetonide	47	30
Pioglitazone Hcl	Pioglitazone Hcl	45	13
Mirtazapine	Mirtazapine	44	12
Finasteride	Finasteride	43	suppressed
Ezetimibe	Ezetimibe	42	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	41	12
Famotidine	Famotidine	35	11
Repaglinide	Repaglinide	34	12
Carvedilol	Carvedilol	33	suppressed
Jardiance	Empagliflozin	33	suppressed
Meloxicam	Meloxicam	31	suppressed
Allopurinol	Allopurinol	29	suppressed
Azithromycin	Azithromycin	29	27
Baclofen	Baclofen	29	11
Citalopram Hbr	Citalopram Hydrobromide	29	suppressed
Donepezil Hcl	Donepezil Hcl	29	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	28	26
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Colchicine	Colchicine	27	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Glipizide	Glipizide	25	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	24	suppressed
Trulicity	Dulaglutide	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	suppressed
Ibandronate Sodium	Ibandronate Sodium	23	suppressed
Telmisartan	Telmisartan	23	suppressed
Meclizine Hcl	Meclizine Hcl	22	16
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Chlorthalidone	Chlorthalidone	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Symbicort	Budesonide/Formoterol Fumarate	21	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	12
Fenofibrate	Fenofibrate	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Alprazolam	Alprazolam	19	suppressed
Irbesartan	Irbesartan	19	suppressed
Nystatin	Nystatin	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Ciprofloxacin-Dexamethasone	Ciprofloxacin Hcl/Dexameth	18	14
Spironolactone	Spironolactone	18	suppressed
Celecoxib	Celecoxib	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Rivastigmine	Rivastigmine	17	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	16
Pregabalin	Pregabalin	16	suppressed
Sucralfate	Sucralfate	16	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Methylprednisolone	Methylprednisolone	15	15
Tresiba Flextouch U-200	Insulin Degludec	15	suppressed
Naproxen	Naproxen	14	suppressed
Topiramate	Topiramate	14	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Cephalexin	Cephalexin	13	12
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Atenolol	Atenolol	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Levemir Flexpen	Insulin Detemir	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Ramipril	Ramipril	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Lactulose	Lactulose	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	11
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	11	suppressed
Temazepam	Temazepam	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error